Latest Non-Redemption Agreements: Bleuacacia and Capitalworks Emerging Markets
Bleuacacia (BLEU) Adds Non-Redemption Agreement
Capitalworks Emerging Markets Acquisition Corp. (CMCA) Adds Non-Redemption Agreement
On May 15, 2023, Capitalworks Emerging Markets Acquisition Corp. (NASDAQ:CMCA) and its sponsor, CEMAC Sponsor LP, entered into non-redemption agreements with certain unaffiliated third parties in exchange for the holders agreeing either not to request redemption, or to reverse any previously submitted redemption demand with respect to an aggregate of 400,000 Class A ordinary shares.
In consideration of the foregoing agreement, immediately prior to, and substantially concurrently with, the closing of an initial business combination, the Sponsor will surrender and forfeit to the company for no consideration an aggregate of 100,000 shares and the company will issue to the holders a number of Class A ordinary shares equal to the Forfeited Shares.
READ
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Heard on the Street: VinFast’s SPAC Backers Are Backing Out Even by the standards of electric-vehicle startups, the $40 billion market value of Vietnamese electric-vehicle startup VinFast is wild, following its combination with Black Spade last month....
Murphy Canyon (NASDAQ:MURF) announced this morning that it has closed its combination with Conduit Pharmaceuticals and its shares and warrants are expected to begin trading on the Nasdaq under the symbols “CDT” and “CDTTW” on September 25. The company also closed a purchase of $20 million in Murphy Canyon units at close, which is to...
Indie Semiconductor (NASDAQ:INDI), which merged with Thunder Bridge II in June 2021, announced this morning that it has launched an exchange offer to convert each outstanding warrant to 0.285 Class A shares in the company. At Indie’s last closing price of $6.22, this is $1.77 of value each, although the stock has been rising since...
Atlantic Coastal II (NASDAQ:ACAB) has entered into a definitive agreement to combine with drug developer Abpro at a valuation of $725 million. Woburn, Massachusetts-based Abpro is advancing a series of drug candidates to potentially treat COVID, cancer and diabetic blindness. The combined company is expected to trade on the Nasdaq once the deal is completed...
Graf Acquisition Corp. IV (NYSE:GFOR) announced that it adjourned Wednesday’s completion vote for its combination with NKGen Biotech without conducting any business and will reopen proceedings at 4:00 p.m., Eastern time, on September 25, 2023 Once again, the adjournment is being done to provide additional time to continue its efforts to obtain additional financing. This new...